Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma

Clinical and Experimental Ophthalmology

Volumn 43, Issue 5, 2015, Pages 415-421

  Wang, Jia Wei ^a   Zhou, Min Wen ^a   Zhang, Xiulan ^a   Huang, Wen Bin ^a   Gao, Xin Bo ^a   Wang, Wei ^a   Chen, Shida ^a   Zhang, Xin Yu ^a   Ding, Xiao Yan ^a   Jonas, Jost B ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Intravitreal ranibizumab; Neovascular glaucoma; Pigment epithelium derived factor; Vascular endothelial growth factor A

Indexed keywords

ANTIGLAUCOMA AGENT; PIGMENT EPITHELIUM DERIVED FACTOR; RANIBIZUMAB; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; VEGFA PROTEIN, HUMAN;

ADULT; AQUEOUS HUMOR; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLAUCOMA DRAINAGE IMPLANT; GLAUCOMA SURGERY; HUMAN; INTERVENTION STUDY; IRIS DISEASE; IRIS NEOVASCULARIZATION; MALE; NEOVASCULAR GLAUCOMA; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA, NEOVASCULAR; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; AQUEOUS HUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PROSPECTIVE STUDIES; RANIBIZUMAB; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84937022498     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12477     Document Type: Article

References (30)

1. Aiello LP, Avery RL, Arrigg PG etal. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
2. Aiello LP, Pierce EA, Foley ED etal. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995; 92: 10457-10461.
3. Rosenfeld PJ, Brown DM, Heier JS etal. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
4. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142: 1054-1056.
5. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006; 26: 354-356.
6. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142: 158-160.
7. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007; 16: 437-439.
8. Wakabayashi T, Oshima Y, Sakaguchi H etal. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115: 1571-1580, 1580.e1-3.
9. Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009; 18: 632-637.
10. Dawson DW, Volpert OV, Gillis P etal. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248.
11. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006; 20: 323-325.
12. Vigneswara V, Berry M, Logan A, Ahmed Z. Pigment epithelium-derived factor is retinal ganglion cell neuroprotective and axogenic after optic nerve crush injury. Invest Ophthalmol Vis Sci 2013; 54: 2624-2633.
13. Sanchez A, Tripathy D, Yin X, Luo J, Martinez J, Grammas P. Pigment epithelium-derived factor (PEDF) protects cortical neurons in vitro from oxidant injury by activation of extracellular signal-regulated kinase (ERK) 1/2 and induction of Bcl-2. Neurosci Res 2012; 72: 1-8.
14. Zhou X, Li F, Kong L, Chodosh J, Cao W. Anti-inflammatory effect of pigment epithelium-derived factor in DBA/2J mice. Mol Vis 2009; 15: 438-450.
15. Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, Kuncl RW. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol 1999; 58: 719-728.
16. Zhang SX, Wang JJ, Gao G, Parke K, Ma JX. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 2006; 37: 1-12.
17. Ohno-Matsui K, Yoshida T, Uetama T, Mochizuki M, Morita I. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 2003; 303: 962-967.
18. Li S, Fu XA, Zhou XF, Chen YY, Chen WQ. Angiogenesis-related cytokines in serum of proliferative diabetic retinopathy patients before and after vitrectomy. Int J Ophthalmol 2012; 5: 726-730.
19. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002; 134: 348-353.
20. Noma H, Mimura T, Eguchi S. Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol 2013; 131: 160-165.
21. Machalinska A, Safranow K, Mozolewska-Piotrowska K, Dziedziejko V, Karczewicz D. PEDF and VEGF plasma level alterations in patients with dry form of age-related degeneration - a possible link to the development of the disease. Klin Oczna 2012; 114: 115-120.
22. Ahn JK, Moon HJ. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration. Am J Ophthalmol 2009; 148: 718-724, e1.
23. Shin YJ, Nam WH, Park SE, Kim JH, Kim HK. Aqueous humor concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in high myopic patients. Mol Vis 2012; 18: 2265-2270.
24. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001; 489: 270-276.
25. Zhou M, Chen S, Wang W etal. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci 2013; 54: 3874-3879.
26. Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 2009; 93: 273-274.
27. Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, Matsumura M. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol 2009; 53: 243-248.
28. Lim TH, Bae SH, Cho YJ, Lee JH, Kim HK, Sohn YH. Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol 2009; 23: 188-192.
29. Sasamoto Y, Oshima Y, Miki A etal. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study. J Ocul Pharmacol Ther 2012; 28: 41-48.
30. Pons M, Marin-Castano ME. Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD. Invest Ophthalmol Vis Sci 2011; 52: 3842-3853.